首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1677950

肝素市場規模、佔有率及成長分析（依產品類型、給藥方式、來源、條件、產品、治療方法、分銷管道、應用、最終用戶和地區）－2025-2032 年產業預測

Heparin Market Size, Share, and Growth Analysis, By Product Type, By Mode of Administration, By Source, By Ingredient, By Availability, By Treatment, By Distribution Channel, By Application, By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年03月05日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球肝素市場規模為 71 億美元，預計將從 2024 年的 74.1 億美元成長到 2032 年的 103.7 億美元，預測期間（2025-2032 年）的複合年成長率為 4.3%。

全球肝素市場主要受到心血管疾病盛行率上升、人口老化以及外科手術激增的推動，使其成為醫療保健和製藥行業的重要組成部分。文明病的增加推動了對抗凝劑的需求，尤其是肝素，它對於治療這些疾病至關重要。住院率和手術干預等因素進一步推動了市場成長。然而，監管監督、市場競爭以及肝素誘發的血小板減少性疾病併發症相關風險等挑戰構成了重大障礙。然而，由於生物相似藥的發展、藥物輸送機制的進步以及新興市場的成長所帶來的機會，預計市場將會成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Opocrin SpA（Italy）
Baxter International Inc.（US）
Pfizer Inc.（US）
Bioiberica SAU（Spain）
Fresenius SE & Co. KGaA（Germany）
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.（China）
B. Braun SE（Germany）
Dr. Reddy's Laboratories Ltd.（India）
LEO Pharma A/S（Denmark）
Aspen Holdings（South Africa）
Gland Pharma（India）
Hikma Pharmaceuticals（United Kingdom）
Techdow USA（US）
Viatris Inc.（US）
Biological E. Limited（India）
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.（China）
Faran Shimi Pharmaceutical Company（Iran）
Octapharma AG（Switzerland）
Kamada Ltd.（Israel）

結論和建議

簡介目錄

Product Code: SQMIG35H2166

Global Heparin Market size was valued at USD 7.1 billion in 2023 and is poised to grow from USD 7.41 billion in 2024 to USD 10.37 billion by 2032, growing at a CAGR of 4.3% during the forecast period (2025-2032).

The global heparin market is a critical component of the healthcare and pharmaceutical sectors, driven primarily by the increasing prevalence of cardiovascular diseases, an aging population, and a surge in surgical procedures. The rising incidence of lifestyle-related illnesses is elevating the demand for anticoagulants, particularly heparin, which is essential for managing these conditions. Factors such as higher hospitalization rates and surgical interventions further bolster market growth. However, challenges such as regulatory scrutiny, market competition, and risks associated with complications, including heparin-induced thrombocytopenia, pose significant hurdles. Nevertheless, the market is expected to thrive due to opportunities arising from the development of biosimilars, advancements in drug delivery mechanisms, and growth in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Heparin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Heparin Market Segments Analysis

Global Heparin Market is segmented by Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User and region. Based on Product Type, the market is segmented into Unfractionated Heparin, Low Molecular Weight Heparin (LMWH) and Ultra-Low Molecular Weight Heparin (ULMWH). Based on Mode of Administration, the market is segmented into Oral Administration and Parenteral Administration. Based on Source, the market is segmented into Bovine and Porcine. Based on Ingredient, the market is segmented into Sodium, Calcium and Others. Based on Availability, the market is segmented into Raw and Processed. Based on Treatment, the market is segmented into Deep Vein Thrombosis, Pulmonary Embolism, Arterial Thromboembolism and Others. Based on Therapeutics, the market is segmented into Cardiovascular, Respiratory, Oncology, Nephrology, CNS and Others. Based on Strength, the market is segmented into 10 -1000 Unit, 1000 -5000 Unit, 5000- 25000 Unit and Others. Based on Type, the market is segmented into Generics and Brands. Based on Container, the market is segmented into Bottles, Bags, Vials and Others. Based on Packaging, the market is segmented into Glass and Plastic. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Drug Store, Online Pharmacy and Others. Based on Application, the market is segmented into Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Diagnostic Tests and Others. Based on End User, the market is segmented into Hospitals, Clinics, Homecare, Ambulatory Surgical Centres and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Heparin Market

The global heparin market is primarily driven by the prevalence of cardiovascular diseases, which remain a leading cause of death and illness worldwide. Conditions such as heart attacks, atrial fibrillation, and strokes significantly heighten the risk of thromboembolic complications, thereby boosting the need for anticoagulants like heparin. Additionally, the rising incidence of pulmonary embolism (PE) and deep vein thrombosis (DVT) further fuels the demand for heparin, as it is widely recognized as the standard treatment for these conditions. As a result, the growing focus on cardiovascular health and related disorders continues to propel the heparin market forward.

Restraints in the Global Heparin Market

The global heparin market faces significant restraints primarily due to the severe side effects associated with heparin therapy, particularly the risk of bleeding, which can lead to patient hesitance and concerns among healthcare providers regarding its use. Additionally, conditions such as Heparin-Induced Thrombocytopenia (HIT) can result in serious complications, thereby undermining the confidence in and safety of heparin treatment. Furthermore, the requirement for continuous monitoring of activated partial thromboplastin time (aPTT) with unfractionated heparin to prevent adverse effects and ensure therapeutic efficacy complicates treatment regimens, particularly in outpatient settings, thereby limiting its wide-scale adoption.

Market Trends of the Global Heparin Market

The global heparin market is experiencing a significant shift with a heavy focus on biosimilars, driven by the expiry of patents for original heparin products. This trend is particularly pronounced in Europe and North America, where healthcare providers seek cost-effective alternatives that maintain safety and efficacy. The rise in biosimilars allows for reduced treatment costs, further enhancing patient access to necessary anticoagulant therapies. As regulatory bodies continue to streamline the approval process for these biosimilars, the heparin market is poised for substantial growth, reflecting a broader move towards cost-efficient healthcare solutions while prioritizing patient outcomes.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Heparin Market Size by Product Type & CAGR (2025-2032)

Market Overview
Unfractionated Heparin
Low Molecular Weight Heparin (LMWH)
Ultra-Low Molecular Weight Heparin (ULMWH)

Global Heparin Market Size by Mode of Administration & CAGR (2025-2032)

Market Overview
Oral Administration
Parenteral Administration

Global Heparin Market Size by Source & CAGR (2025-2032)

Market Overview
Bovine
Porcine

Global Heparin Market Size by Ingredient & CAGR (2025-2032)

Market Overview
Sodium
Calcium
Others

Global Heparin Market Size by Availability & CAGR (2025-2032)

Market Overview
Raw
Processed

Global Heparin Market Size by Treatment & CAGR (2025-2032)

Market Overview
Deep Vein Thrombosis
Pulmonary Embolism
Arterial Thromboembolism
Others

Global Heparin Market Size by Therapeutics & CAGR (2025-2032)

Market Overview
Cardiovascular
Respiratory
Oncology
Nephrology
CNS
Others

Global Heparin Market Size by Strength & CAGR (2025-2032)

Market Overview
10 -1000 Unit
1000 -5000 Unit
5000- 25000 Unit
Others

Global Heparin Market Size by Type & CAGR (2025-2032)

Market Overview
Generics
Brands

Global Heparin Market Size by Container & CAGR (2025-2032)

Market Overview
Bottles
Bags
Vials
Others

Global Heparin Market Size by Packaging & CAGR (2025-2032)

Market Overview
Glass
Plastic

Global Heparin Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacy
Retail Pharmacy and Drug Store
Online Pharmacy
Others

Global Heparin Market Size by Application & CAGR (2025-2032)

Market Overview
Pre-Surgical Procedures
Post-Surgical Procedures
Kidney Dialysis
Diagnostic Tests
Others

Global Heparin Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Homecare
Ambulatory Surgical Centres
Others

Global Heparin Market Size & CAGR (2025-2032)

North America (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
- US
- Canada
Europe (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Opocrin S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioiberica S.A.U. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
B. Braun SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LEO Pharma A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aspen Holdings (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gland Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Techdow USA (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biological E. Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Faran Shimi Pharmaceutical Company (Iran)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kamada Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments